ReviewDrugs in context2026
GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) - beyond weight loss: a condensed scientific review.
Review in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than half of cases of heart failure (HF) now occur with preserved ejection fraction (HFpEF), a heterogeneous syndrome strongly influenced by comorbidities such as obesity, hypertension, diabetes and atrial fibrillation. Despite recent evidence supporting SGLT2 inhibitors and mineralocorticoid receptor antagonists, morbidity and mortality remain substantial. GLP1 receptor agonists, initially developed for type 2 diabetes, induce profound weight loss and have demonstrated benefits across cardiovascular, renal and metabolic pathways relevant to HFpEF. Recent randomized controlled trials (RCTs) in obesity-related HFpEF showed clinically meaningful improvements in symptoms, functional capacity and inflammatory biomarkers with semaglutide in STEP-HFpEF, and a reduction in the composite of cardiovascular death or worsening HF events with tirzepatide in SUMMIT. Mechanistic evidence suggests effects on natriuresis, inflammation, cardiac remodelling, endothelial function and epicardial adipose tissue quality and volume. This review summarizes the pathophysiological rationale, clinical evidence, mechanistic insights and therapeutic positioning of GLP1 receptor agonists in HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.